Relationship between IgM antibody to human cytomegalovirus, virus load, donor and recipient serostatus, and administration of methylprednisolone as risk factors for cytomegalovirus disease after liver transplantation

Journal of Infectious Diseases

Volumn 182, Issue 6, 2000, Pages 1610-1615

  Chou, Sunwen ^a,b   Miner, Richard C ^c   Drew, W Lawrence ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN M; METHYLPREDNISOLONE;

ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; GRAFT REJECTION; HUMAN; INFECTION RISK; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; VIRUS LOAD;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, VIRAL; COHORT STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE PROGRESSION; DNA, VIRAL; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN M; LIVER TRANSPLANTATION; METHYLPREDNISOLONE; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATIONS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEROLOGIC TESTS; TIME FACTORS; TISSUE DONORS; VIRAL LOAD;

EID: 0033695834     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/317636     Document Type: Article

References (38)

1. Infections in solid-organ transplant recipients
2. Cytomegalovirus
3. Cytomegalovirus hepatitis in liver transplantation: Prospective analysis of 93 consecutive orthotopic liver transplantations
4. Prognostic significance and risk factors of untreated cytomegalovirus viremia in liver transplant recipients
5. Donated organ as a source of cytomegalovirus in orthotopic liver transplantation
6. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation
7. Solid organ transplantation: Results and implications of acyclovir use in liver transplants
8. Prediction of recurrent cytomegalovirus disease after treatment with ganciclovir in solid-organ transplant recipients
9. High dose acyclovir compared with shortcourse pre-emptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients
10. Randomized comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver transplant recipients
11. Cytomegalovirus prophylaxis strategies in high-risk transplantation
12. A randomized prospective trial of acyclovir and the immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy
13. Relationship of the polymerase chain reaction for cytomegalovirus to the development of hepatitis in liver transplant recipients
14. Clinical use of a PCR test for detection of CMV DNA in leukocyte and serum samples
15. Cytomegalovirus disease after transplantation: Diagnosis and therapy
16. Demonstration of cytomegalovirus by polymerase chain reaction after liver transplantation
17. Detection of cytomegalovirus DNA in the sera of liver transplant recipients
18. Comparison of polymerase chain reaction from plasma and bully coat with antigen detection and occurrence of immunoglobulin M for the demonstration of cytomegalovirus infection after liver transplantation
19. A prospective comparison of molecular diagnostic techniques for the early detection of cytomegalovirus in liver transplant recipients
20. Inter-relationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation
21. Time to detection of cytomegalovirus (CMV) DNA in blood leukocytes is a predictor for the development of CMV disease in CMV-seronegative recipients of allografts from CMV-seropositive donors following liver transplantation
22. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. City of Hope-Stanford-Syntex CMV Study Group
23. Comparison of a new quantitative cytomegalovirus DNA assay with other detection methods
24. Comparison of culture and serology for the diagnosis of cytomegalovirus infection in kidney and liver transplant recipients
25. Incidence, distribution, and outcome of episodes of infection in 100 orthotopic liver transplantations
26. Rapid shell vial culture and tissue histology compared with serology for the rapid diagnosis of cytomegalovirus infection in liver transplantation
27. Detection of IgM antibody to cytomegalovirus and rapid diagnosis of this virus infection by the shell vial assay
28. Use of laboratory assays to predict cytomegalovirus disease in renal transplant recipients
29. Recombinant mono- and polyantigens to detect cytomegalovirus-specific immunoglobulin M in human sera by enzyme immunoassay
30. The DNA-binding protein pUL57 of human cytomegalovirus: Comparison of specific immunoglobulin M (IgM) reactivity with IgM reactivity to other major target antigens
31. Development and clinical evaluation of a recombinant-antigen-based cytomegalovirus immunoglobulin M immunoassay using the Abbott AxSYM analyzer
32. Longitudinal analysis of cytomegalovirus load in renal transplant recipients using a quantitative polymerase chain reaction: Correlation with disease
33. Quantification of human cytomegalovirus DNA using the polymerase chain reaction
34. Use of the polymerase chain reaction to analyse sequence variation within a major neutralizing epitope of glycoprotein B (gp58) in clinical isolates of human cytomegalovirus
35. Provision of prognostic information in immunocompromised patients by routine application of the polymerase chain reaction for cytomegalovirus
36. Workshop on CMV disease: Definitions, clinical severity scores, and new syndromes